S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
JPMorgan Chase Falls 5% as Consumer Cracking Begins to Show
NASDAQ:ANIP

ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis

$66.88
-1.23 (-1.81%)
(As of 05:21 PM ET)
Today's Range
$66.41
$68.17
50-Day Range
$55.02
$69.69
52-Week Range
$36.99
$70.81
Volume
94,984 shs
Average Volume
139,273 shs
Market Capitalization
$1.41 billion
P/E Ratio
79.62
Dividend Yield
N/A
Price Target
$80.00

ANI Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
19.6% Upside
$80.00 Price Target
Short Interest
Healthy
0.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.48
Upright™ Environmental Score
News Sentiment
0.77mentions of ANI Pharmaceuticals in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$9.29 M Sold Last Quarter
Proj. Earnings Growth
16.62%
From $3.55 to $4.14 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.90 out of 5 stars

Medical Sector

73rd out of 2,784 stocks

Pharmaceutical Preparations Industry

31st out of 1,293 stocks

ANIP stock logo

About ANI Pharmaceuticals Stock (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

ANIP Stock Price History

ANIP Stock News Headlines

Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
3 Biotech Stocks Gaining Altitude and Interest
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
ANI Pharmaceuticals Inc
Expert Outlook: ANI Pharmaceuticals Through The Eyes Of 4 Analysts
See More Headlines
Receive ANIP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/12/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ANIP
Previous Symbol
NASDAQ:BPAX
Employees
642
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$80.00
High Stock Price Target
$83.00
Low Stock Price Target
$77.00
Potential Upside/Downside
+18.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$18.78 million
Pretax Margin
4.08%

Debt

Sales & Book Value

Annual Sales
$486.82 million
Cash Flow
$6.50 per share
Book Value
$21.13 per share

Miscellaneous

Free Float
15,071,000
Market Cap
$1.43 billion
Optionable
Optionable
Beta
0.79
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

ANIP Stock Analysis - Frequently Asked Questions

Should I buy or sell ANI Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANIP shares.
View ANIP analyst ratings
or view top-rated stocks.

What is ANI Pharmaceuticals' stock price target for 2024?

4 brokerages have issued 12-month target prices for ANI Pharmaceuticals' stock. Their ANIP share price targets range from $77.00 to $83.00. On average, they predict the company's share price to reach $80.00 in the next twelve months. This suggests a possible upside of 19.6% from the stock's current price.
View analysts price targets for ANIP
or view top-rated stocks among Wall Street analysts.

How have ANIP shares performed in 2024?

ANI Pharmaceuticals' stock was trading at $55.14 on January 1st, 2024. Since then, ANIP shares have increased by 21.3% and is now trading at $66.88.
View the best growth stocks for 2024 here
.

Are investors shorting ANI Pharmaceuticals?

ANI Pharmaceuticals saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 197,000 shares, a drop of 24.7% from the March 15th total of 261,600 shares. Based on an average daily volume of 137,600 shares, the short-interest ratio is presently 1.4 days.
View ANI Pharmaceuticals' Short Interest
.

When is ANI Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ANIP earnings forecast
.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) announced its earnings results on Thursday, February, 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. ANI Pharmaceuticals had a net margin of 3.86% and a trailing twelve-month return on equity of 18.06%.

What ETFs hold ANI Pharmaceuticals' stock?
What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY24 earnings guidance on Tuesday, March, 12th. The company provided EPS guidance of $4.26-4.67 for the period, compared to the consensus estimate of $4.46. The company issued revenue guidance of $520-542 million, compared to the consensus revenue estimate of $535.21 million.

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

5 employees have rated ANI Pharmaceuticals Chief Executive Officer Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among the company's employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 49.0% of employees surveyed would recommend working at ANI Pharmaceuticals to a friend.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.12%) and BTC Capital Management Inc. (0.04%). Insiders that own company stock include Antonio R Pera, Chad Gassert, James G Marken, Jeanne Thoma, Krista Davis, Meredith Cook, Meridian Venture Partners Ii L, Muthusamy Shanmugam, Nikhil Lalwani, Ori Gutwerg, Patrick D Walsh, Stephen P Carey and Thomas Haughey.
View institutional ownership trends
.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ANIP) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners